45094 studies found for:    "Molecular Mechanisms of Pharmacological Action"
Show Display Options
Rank Status Study
1 Recruiting Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
Condition: Breast Cancer
Interventions: Device: Focused Microwave Thermotherapy;   Drug: Chemotherapy (control)
2 Completed Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV
Condition: Chronic Hepatitis C Virus
Interventions: Drug: LDV/SOF;   Drug: RBV
3 Active, not recruiting Tecemotide (L-BLP25) in Rectal Cancer
Condition: Rectal Cancer
Interventions: Other: Chemoradiation Therapy;   Drug: Cyclophosphamide (CPA);   Other: Biological: Tecemotide (L-BLP25)
4 Recruiting Modufolin (6R 5,10-Methylenetetrahydrofolate) and Pemetrexed for Neoadjuvant Rectal Cancer Treatment
Condition: Rectal Cancer
Interventions: Drug: [6R] 5,10-methylenetetrahydrofolate;   Drug: Pemetrexed
5 Recruiting Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
Condition: Stage IV Colorectal Cancer
Intervention: Drug: Vitamin C
6 Completed
Has Results
Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)
Condition: Myelodysplastic Syndromes
Intervention: Drug: Azacitidine
7 Recruiting Erlotinib Versus Gefitinib in Advanced Non Small Cell Lung Cancer With exon21 Mutation:A Randomized Trial
Condition: Thoracic Neoplasms
Intervention: Drug: erlotinib,gefitinib
8 Recruiting Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Conditions: Lung Cancer;   Non Small Cell Lung Cancer.
Interventions: Drug: Patritumab;   Drug: erlotinib:;   Drug: Placebo
9 Recruiting The Effects of Pravastatin and Rosuvastatin on Coronary Plaques in Patients With Stable Angina Pectoris
Conditions: Coronary Disease;   Hypercholesterolemia
Intervention: Drug: pravastatin, rosuvastatin
10 Approved for marketing Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C
Condition: Post-transplant Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: Ribavirin;   Drug: Pegylated Interferon
11 Completed Medications Development for the Treatment of Cannabis Related Disorders
Conditions: Nicotine Withdrawal;   Marijuana Dependence;   Cannabis Dependence;   Nicotine Dependence;   Cannabis Abuse
Interventions: Drug: Placebo Aprepitant;   Drug: Active Aprepitant
12 Completed A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer
Conditions: Breast Neoplasms;   Neoplasms;   Neoplasms by Site;   Breast Diseases;   Skin Diseases
Intervention: Drug: ET743
13 Completed Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)
Condition: Chronic Hepatitis C Virus
Interventions: Drug: LDV/SOF;   Drug: RBV
14 Unknown  Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction.
Condition: ST-Segment Elevation Myocardial Infarction
Interventions: Drug: Ezetimibe;   Drug: Placebo
15 Not yet recruiting Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse
Condition: Cocaine Dependence
Interventions: Drug: Doxazosin;   Drug: Placebo
16 Recruiting Tranexamic Acid in Reverse Total Shoulder Arthroplasty
Conditions: Shoulder Joint Disease;   Complications; Arthroplasty;   Intraoperative Complications;   Blood Loss, Surgical
Intervention: Drug: Infusion Tranexamic acid or placebo.
17 Completed A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
Conditions: Malignant Solid Tumor;   Lymphomas;   Multiple Myeloma
Interventions: Biological: AV-299;   Biological: AV-299 + erlotinib
18 Completed Caffeine for Motor Manifestations of Parkinson's Disease
Condition: Parkinson's Disease
Intervention: Drug: Caffeine alkaloid
19 Completed Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
Conditions: Endometrial Neoplasms;   Uterine Neoplasms;   Genital Neoplasms, Female Urogenital Neoplasms
Interventions: Drug: Trabectedin;   Drug: Dexamethasone
20 Active, not recruiting Study of Vorinostat (MK-0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma (MK-0683-088 AMN)
Condition: Multiple Myeloma
Interventions: Drug: vorinostat;   Drug: bortezomib;   Drug: placebo to vorinostat

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years